• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Glovan
    / Teva


    Active Ingredient *

    Status in Israel
    OTC

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Vaginal Ovules

    12

    not in the basket chart 20742 7202

    Dosage

    1 Glovan ovule should be inserted 15-30 minutes prior to intercourse, as deep as possible into the vagina. If intercourse is repeated, another Glovan ovule should be inserted, in the same way.
    If vaginal douching is desired, it should be delayed for 6 hours following intercourse, to avoid washing out the spermicidal protection.
    If intercourse is delayed for more than an hour after insertion of the ovule, a new one should be used.
    The ovule may be wetted with a little water to ease insertion and prevent irritation.


    Indications

    Spermicide contraceptive.


    Contra-Indications

    Known hypersensitivity to either of the components of the preparation.
    Vaginal anesthesia, as in spinal cord injuries.
    Pregnancy.


    Special Precautions

    See prescribing information for full details.


    Side Effects

    Some local irritation (allergic vaginitis, contact dermatitis) to the female or male
    genitalia may occur occasionally. Urinary tract infection in females may also occur.


    Overdose

    If taken orally, the surfactant properties of this preparation may cause gastric
    irritation. General supportive therapy should be carried out. Hepatic and renal
    function should be monitored if medically indicated.


    Manufacturer
    Teva Pharmaceutical Industries Ltd, Israel
    CLOSE